Cymbalta(R) Gets FDA Approval For Treatment of Generalized Anxiety Disorder

It looks as if Cymbalta is getting close to being an “everything-anything” drug when it comes to treating depression. Generalized Anxiety Disorder, or GAD is now a “chronic condition”? In reading the last paragraph about the problems, it appears the economy and our current state of affairs could almost lay this diagnosis on anyone of us, controlling worry, irritability, sleep disturbance, and poor concentration. I think we are creating some of the poor concentration these days too with what we are expecting from others at times too.

I states that this could be a disorder if all of the above continue on for longer than 6 months, well let’s see it has been over a year since the crash of the stock market so in those terms does it mean we are all candidates? (grin). It’s going to take more than Cymbalta to cure this depression. BD

NDIANAPOLIS, Nov. 30 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) has approved Cymbalta® (duloxetine HCl) for the maintenance treatment of generalized anxiety disorder (GAD) in adults, Eli Lilly and Company (NYSE: LLY) announced today.

"Since generalized anxiety disorder can be a chronic illness, it is important that doctors and their patients find a treatment option that is effective in both the acute and maintenance phase of treatment," said James M. Martinez, MD, U.S. Medical Director for Cymbalta. "With this additional approval, Cymbalta offers a new option for the maintenance treatment of this often-debilitating condition."

Cymbalta also is approved for the acute and maintenance treatment of major depressive disorder, the management of diabetic peripheral neuropathic pain and fibromyalgia, and for the acute treatment of generalized anxiety disorder, all in adults.

Generalized anxiety disorder affects nearly 7 million Americans at any given time.(i) While the symptoms of GAD can vary from person to person, they may include excessive worry or anxiety over a period of six months or longer, difficulties controlling worry, irritability, poor concentration, sleep disturbances, fatigue, restlessness and muscle tension.(ii) If left untreated, symptoms may get progressively worse.(iii) Additionally, GAD can have a negative impact on a person's ability to function well in work, family and social situations.(iv)

FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety